Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financial Disclosure Guidance Should Put Less Burden On Sponsors - HIMA

This article was originally published in The Gray Sheet

Executive Summary

FDA should revise its draft guidance on financial disclosures by clinical investigators to ensure that clinical data is not rejected if a sponsor is unable to obtain financial information from foreign investigators, the Health Industry Manufacturers Association contends in Dec. 23 comments to the agency.

You may also be interested in...

Clinical investigator financial disclosure

FDA guidance document encourages industry to collect financial records from their clinical trial investigators "in as efficient and least burdensome manner as possible," suggesting the use of questionnaires as opposed to "elaborate internal computerized tracking systems." Disclosure of compensation to clinical investigators conducting studies of products, as well as the investigators' financial interests in study sponsor companies, is required under a Feb. 2 rule. The agency is requesting comments on the guidance, which also addresses industry concerns about the costs of collecting and maintaining the financial records

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts